Prothena (PRTA) Short Interest Ratio & Short Volume → CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad) Free PRTA Stock Alerts $22.52 -0.87 (-3.72%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Prothena Short Interest DataCurrent Short Volume6,750,000 sharesPrevious Short Volume6,630,000 sharesChange Vs. Previous Month+1.81%Dollar Volume Sold Short$137.30 millionShort Interest Ratio / Days to Cover11.1Last Record DateApril 30, 2024Outstanding Shares53,772,000 sharesPercentage of Shares Shorted12.55%Today's Trading Volume423,160 sharesAverage Trading Volume530,580 sharesToday's Volume Vs. Average80% Short Selling Prothena ? Sign up to receive the latest short interest report for Prothena and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatPRTA Short Interest Over TimePRTA Days to Cover Over TimePRTA Percentage of Float Shorted Over Time Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. Prothena Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20246,750,000 shares $137.30 million +1.8%N/A11.1 $20.34 4/15/20246,630,000 shares $145.79 million +2.5%N/A10.1 $21.99 3/31/20246,470,000 shares $160.26 million +3.5%N/A8.1 $24.77 3/15/20246,250,000 shares $162.94 million +3.0%N/A7.6 $26.07 2/29/20246,070,000 shares $167.47 million +4.5%N/A7 $27.59 2/15/20245,810,000 shares $165.70 million +1.0%N/A6.6 $28.52 Get the Latest News and Ratings for PRTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. 1/31/20245,750,000 shares $163.24 million -8.2%N/A6.8 $28.39 1/15/20246,260,000 shares $217.03 million +3.0%N/A7 $34.67 12/31/20236,080,000 shares $220.95 million +4.5%N/A6.8 $36.34 12/15/20235,820,000 shares $232.74 million -15.0%N/A7.6 $39.99 11/30/20236,850,000 shares $223.17 million +10.7%N/A10.1 $32.58 11/15/20236,190,000 shares $217.15 million -4.8%N/A9.6 $35.08 10/31/20236,500,000 shares $236.99 million +28.0%N/A10.6 $36.46 10/15/20235,080,000 shares $223.93 million +15.7%N/A10.4 $44.08 9/30/20234,390,000 shares $211.82 million +2.6%N/A10.7 $48.25 9/15/20234,280,000 shares $224.53 million +3.9%N/A11.2 $52.46 8/31/20234,120,000 shares $217.62 million +11.4%N/A10.6 $52.82 8/15/20233,700,000 shares $223.33 million +0.8%N/A9.4 $60.36 7/31/20233,670,000 shares $252.75 million +0.8%N/A9 $68.87 7/15/20233,640,000 shares $254.84 million +3.4%N/A8.3 $70.01 6/30/20233,520,000 shares $240.35 million -4.4%N/A7.9 $68.28 6/15/20233,680,000 shares $267.06 million +10.8%N/A7.8 $72.57 5/31/20233,320,000 shares $220.55 million +3.4%N/A7.1 $66.43 5/15/20233,210,000 shares $240.65 million -1.8%N/A6.7 $74.97 4/30/20233,270,000 shares $172.07 million No ChangeN/A6.9 $52.62 4/15/20233,270,000 shares $164.91 million -11.9%N/A7.5 $50.43 3/31/20233,710,000 shares $179.82 million +7.5%N/A8.3 $48.47 3/15/20233,450,000 shares $169.15 million +11.7%N/A6.9 $49.03 2/28/20233,090,000 shares $172.30 million +4.4%N/A5.9 $55.76 2/15/20232,960,000 shares $159.60 million +6.5%N/A5.6 $53.92 1/31/20232,780,000 shares $157.21 million -3.5%N/A5 $56.55 1/15/20232,880,000 shares $163.87 million +9.1%N/A5 $56.90 12/30/20222,640,000 shares $159.06 million +9.5%N/A4.4 $60.25 12/15/20222,410,000 shares $141.03 million +6.6%N/A2.9 $58.52 11/30/20222,260,000 shares $141.27 million +1.4%N/A2.7 $62.51 11/15/20222,230,000 shares $138.64 million -8.2%N/A2.7 $62.17 10/31/20222,430,000 shares $149.30 million -10.7%N/A3.1 $61.44 10/15/20222,720,000 shares $149.19 million -16.6%6.2%3.7 $54.85 9/30/20223,260,000 shares $197.65 million +32.5%7.4%4.8 $60.63 9/15/20222,460,000 shares $73.80 million -8.2%5.6%6.5 $30.00I’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film.Take a look. PRTA Short Interest - Frequently Asked Questions What is Prothena's current short interest? Short interest is the volume of Prothena shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 6,750,000 shares of PRTA short. Learn More on Prothena's current short interest. What is a good short interest ratio for Prothena? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PRTA shares currently have a short interest ratio of 11.0. Learn More on Prothena's short interest ratio. Which institutional investors are shorting Prothena? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Prothena: Ikarian Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Prothena's short interest increasing or decreasing? Prothena saw a increase in short interest in April. As of April 30th, there was short interest totaling 6,750,000 shares, an increase of 1.8% from the previous total of 6,630,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Prothena's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Prothena: Enliven Therapeutics, Inc. (18.60%), AbCellera Biologics Inc. (11.31%), Verona Pharma plc (7.56%), Collegium Pharmaceutical, Inc. (21.78%), Mirum Pharmaceuticals, Inc. (18.04%), Ironwood Pharmaceuticals, Inc. (13.04%), Innoviva, Inc. (18.39%), Cassava Sciences, Inc. (28.91%), Belite Bio, Inc (0.06%), MannKind Co. (13.13%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Prothena stock? Short selling PRTA is an investing strategy that aims to generate trading profit from Prothena as its price is falling. PRTA shares are trading down $0.87 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Prothena? A short squeeze for Prothena occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PRTA, which in turn drives the price of the stock up even further. How often is Prothena's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PRTA, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Enliven Therapeutics Short Squeeze AbCellera Biologics Short Squeeze Verona Pharma Short Squeeze Collegium Pharmaceutical Short Squeeze Mirum Pharmaceuticals Short Squeeze Ironwood Pharmaceuticals Short Squeeze Innoviva Short Squeeze Cassava Sciences Short Squeeze Belite Bio Short Squeeze MannKind Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PRTA) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingObama’s Forever Term [exposed]Porter & Company4 Cryptos BETTER than BitcoinTrue Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMissed NVDA? Buy this AI stock NOWChaikin Analytics